Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5882966 | Clinical Lymphoma Myeloma and Leukemia | 2014 | 7 Pages |
Abstract
Multiple myeloma (MM) is a clonal plasma cell malignancy. Although MM is still not completely curable, it can be maintained at the level of a long-term chronic condition. Irrespective of the treatment strategy, relapse is still a major problem for most patients. Approximately 10% to 15% of all MM patients relapse early and have poor prognosis and outcome. Currently, there are many ways of identifying these high-risk patients using cytogenetics or molecular biology. Despite these various approaches to definition of high risk patients, a clear definition of high-risk MM has not been widely accepted. In this review, we discuss and compare various approaches, and their strengths and weaknesses in early identification of high-risk MM patients.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Helena Paszekova, Fedor Kryukov, Lenka Kubiczkova, Roman Hajek, Sabina Sevcikova,